Monopar Therapeutics Files 8-K: Material Agreement & Equity Sales

TL;DR

Monopar inked a material deal and sold some stock, filing details with the SEC.

AI Summary

Monopar Therapeutics Inc. entered into a material definitive agreement on December 20, 2024. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. Specific details of the agreement and sales were not provided in this excerpt.

Why It Matters

This filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial standing and future operations.

Risk Assessment

Risk Level: medium — The filing indicates material definitive agreements and unregistered sales of equity, which can carry inherent risks and require further investigation into the specifics.

Key Players & Entities

• Monopar Therapeutics Inc. (company) — Registrant
• December 20, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value MNPR The Nasdaq Stock Mar
• $23.79 — ommon Stock "), at an offering price of $23.79 per Share (the " Registered Offering ")
• $23.789 — of Common Stock at a purchase price of $23.789 per pre-funded warrant, which represent
• $37.6 million — enses, are expected to be approximately $37.6 million. The Registered Offering and the Privat

Filing Documents

• mnpr20241220_8k.htm (8-K) — 37KB
• ex_760197.htm (EX-1.1) — 216KB
• ex_760186.htm (EX-4.1) — 88KB
• ex_759781.htm (EX-5.1) — 10KB
• ex_760188.htm (EX-10.1) — 240KB
• ex_760187.htm (EX-10.2) — 107KB
• 0001437749-24-038286.txt ( ) — 993KB
• mnpr-20241220.xsd (EX-101.SCH) — 3KB
• mnpr-20241220_def.xml (EX-101.DEF) — 12KB
• mnpr-20241220_lab.xml (EX-101.LAB) — 16KB
• mnpr-20241220_pre.xml (EX-101.PRE) — 12KB
• mnpr20241220_8k_htm.xml (XML) — 3KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. Underwritten Registered Offering On December 20, 2024, Monopar Therapeutics Inc., a Delaware corporation (the " Company "), entered into an Underwriting Agreement (the " Underwriting Agreement ") with Piper Sandler & Co. (the " Representative ") as Representative of the several underwriters named therein (together with the Representative, the " Underwriters "), pursuant to which the Company will issue and sell to the Underwriters pursuant to the Underwriting Agreement 798,655 shares (the " Shares ") of common stock, par value $0.001 per share (the " Common Stock "), at an offering price of $23.79 per Share (the " Registered Offering "). The Registered Offering is being made pursuant to a shelf registration statement filed December 21, 2022 and declared effective by the Securities and Exchange Commission (the " SEC ") on January 4, 2023 (the " Registration Statement ") (File. No. 333-268935), a base prospectus filed as part thereof, and a prospectus supplement dated December 20, 2024, filed pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the " Securities Act "). The Underwriting Agreement contains customary representations, warranties and agreements by the Company and the Underwriters, customary conditions to closing, and customary indemnification obligations of the Company. The Company has agreed to provide the Underwriters with customary indemnification and contribution rights, in connection with entering into the Underwriting Agreement. The Company also agreed to reimburse the Underwriters for certain expenses. The foregoing description of the Underwriting Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference. The opinion of the Company's counsel regarding the validity of the Shares to be issued pursua

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities The information in Item 1.01 above is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated December 20, 2024, by and among Monopar Therapeutics Inc., Piper Sandler & Co. and the underwriters named therein. 4.1 Form of Pre-Funded Warrant 5.1 Legal Opinion of Baker & Hostetler LLP 10.1 Securities Purchase Agreement, dated December 20, 2024, by and among Monopar Therapeutics Inc. and the Purchaser 10.2 Form of Registration Rights Agreement by and among Monopar Therapeutics Inc. and the Purchaser 23.1 Consent of Baker & Hostetler LLP (contained in Exhibit 5.1). 104 Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monopar Therapeutics Inc. Date: December 23, 2024 By: /s/ Karthik Radhakrishnan Name: Karthik Radhakrishnan Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR